BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17474358)

  • 1. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies.
    Duvic M
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):33-40. PubMed ID: 17474358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of cutaneous T cell lymphoma: current status and future directions.
    Apisarnthanarax N; Talpur R; Duvic M
    Am J Clin Dermatol; 2002; 3(3):193-215. PubMed ID: 11978140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
    Duvic M
    Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novel treatment modalities in cutaneous T cell lymphoma. Biologic response modifiers].
    Marschalkó M
    Orv Hetil; 2005 Jun; 146(23):1251-5. PubMed ID: 15988920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of refractory early-stage cutaneous T-cell lymphoma.
    Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
    Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of rexinoids.
    Foss F
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S21-5. PubMed ID: 16516672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denileukin diftitox.
    Saxon M
    Clin J Oncol Nurs; 2000; 4(6):289, 293. PubMed ID: 11899329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical and systemic retinoid therapy for cutaneous T-cell lymphoma.
    Kempf W; Kettelhack N; Duvic M; Burg G
    Hematol Oncol Clin North Am; 2003 Dec; 17(6):1405-19. PubMed ID: 14710892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
    Talpur R; Jones DM; Alencar AJ; Apisarnthanarax N; Herne KL; Yang Y; Duvic M
    J Invest Dermatol; 2006 Mar; 126(3):575-83. PubMed ID: 16410787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of cutaneous T-cell lymphoma.
    Zackheim HS
    Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic approaches in cutaneous lymphoma.
    Jörg B; Kerl H; Thiers BH; Bröcker EB; Burg G
    Dermatol Clin; 1994 Apr; 12(2):433-41. PubMed ID: 8045054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma.
    Duvic M; Apisarnthanarax N; Cohen DS; Smith TL; Ha CS; Kurzrock R
    J Am Acad Dermatol; 2003 Jul; 49(1):35-49. PubMed ID: 12833006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).
    Duvic M; Kuzel TM; Olsen EA; Martin AG; Foss FM; Kim YH; Heald PW; Bacha P; Nichols J; Liepa A
    Clin Lymphoma; 2002 Mar; 2(4):222-8. PubMed ID: 11970761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
    Talpur R; Duvic M
    Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak) and bexarotene (Targretin): report of a case.
    Kerl K; Prins C; Cerroni L; French LE
    Br J Dermatol; 2006 May; 154(5):988-91. PubMed ID: 16634908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.
    Rook AH; Junkins-Hopkins JM; McGinnis KS; Wysocka M; Richardson SK; Budgin JB; Everitts S; Vittorio CC
    Adv Dermatol; 2002; 18():29-43. PubMed ID: 12528401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
    Dummer R; Foss F; Dreno B; Bagot M
    Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous T cell lymphoma: update of treatment.
    Zackheim HS
    Dermatology; 1999; 199(2):102-5. PubMed ID: 10559573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denileukin diftitox.
    Figgitt DP; Lamb HM; Goa KL
    Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
    Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
    Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.